The clinical utility of ITPA genotyping remains unclear, it may be important in patients with high risk of RBV associated anaemia or related mortality, but until now there is no evidence that ITPA variants are associated with the need of RBV dose modifications or treatment outcome in genotype 2/3 patients [23,24]. This evidence concerns the gene ITPA and anemia (phenotype).